(Q44121927)

30 November 2017

title

An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy (English)

1 reference

30 November 2017

4

Francesco Muntoni

1 reference

30 November 2017

Maria Kinali

1

1 reference

30 November 2017

Eugenio Mercuri

series ordinal

2

1 reference

30 November 2017

Marion Main

series ordinal

3

1 reference

30 November 2017

Victor Dubowitz

series ordinal

5

1 reference

30 November 2017

publication date

1 October 2002

1 reference

30 November 2017

published in

Neuromuscular Disorders

1 reference

30 November 2017

volume

12 Suppl 1

1 reference

30 November 2017

page(s)

S169-74

1 reference

Prednisone in Duchenne muscular dystrophy

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Long-term benefit from prednisone therapy in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Steroids in duchenne muscular dystrophy — Deflazacort trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Prednisone in Duchenne dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Deflazacort in Duchenne dystrophy: study of long-term effect

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

75th European Neuromuscular Centre International Workshop: 2nd workshop on the treatment of muscular dystrophy 10-12 December, 1999, Naarden, The Netherlands.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Deflazacort treatment of Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Remission of clinical signs in early duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Dystrophin-deficient myofibers are vulnerable to mast cell granule-induced necrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Duchenne-like myopathy in double-mutant mdx mice expressing exaggerated mast cell activity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

Therapeutic possibilities in muscular dystrophy: the hope versus the hype

1 reference

https://api.crossref.org/works/10.1016%2FS0960-8966%2802%2900097-4

7 January 2021

10.1016/S0960-8966(02)00097-4

Identifiers

DOI

1 reference

30 November 2017

1 reference